Female Infertility Market Report 2025

This Female Infertility market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The female infertility market size has grown steadily in recent years. It will grow from $1.79 billion in 2024 to $1.87 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth during the historic period can be attributed to several factors, including the growing trend of women delaying childbirth, changes in lifestyle, increased government initiatives, a rising aging population, and the growing use of assisted reproductive technology (ART) treatments.

The female infertility market size is expected to see steady growth in the next few years. It will grow to $2.19 billion in 2029 at a compound annual growth rate (CAGR) of 4.1%. The growth during the forecast period can be attributed to several factors, including rising awareness of fertility issues, an increase in cases of polycystic ovary syndrome, a growing number of uterine abnormalities, a higher incidence of genetic disorders, and increasing obesity. Key trends expected during this period include advancements in preimplantation genetic testing, technological innovations, novel diagnostic technologies, fertility preservation techniques, and the rise of telemedicine.

The growing prevalence of infertility is expected to fuel the expansion of the female infertility market in the coming years. Infertility is defined as the inability to conceive after 12 months of regular, unprotected sexual intercourse. The rise in infertility is influenced by factors such as delayed childbearing, lifestyle changes, environmental toxins, increasing obesity rates, and higher stress levels. Treatment for female infertility is necessary to address and manage the underlying medical, hormonal, or structural issues that hinder fertility, improving the chances of conception and preventing permanent infertility. For example, in July 2024, the Human Fertilization and Embryology Authority, a UK-based public body under the Department of Health and Social Care, reported that licensed fertility clinics in the UK conducted nearly 77,000 fresh and frozen embryo transfer IVF cycles for 52,500 patients in 2022. More than 90% of these patients received treatment with a partner, involving around 100,000 individuals. As a result, the rising prevalence of infertility is driving the growth of the female infertility market.

Key companies in the female infertility market are focusing on developing innovative products, such as non-invasive diagnostic tests, to gain a competitive advantage. A non-invasive diagnostic test is a medical examination that detects conditions or diseases without the need for surgery or penetration of the body. For example, in August 2024, Heranova Lifesciences, a biotech company based in the US, introduced an early access program for HerResolve, a non-invasive diagnostic test designed for endometriosis. Endometriosis affects around 200 million women globally, causing symptoms such as infertility, pain, and bleeding. For many women, an accurate diagnosis takes an average of 7 to 10 years from the onset of symptoms, largely due to the diverse nature of symptoms and the invasive procedure required for the most reliable diagnostic method, exploratory laparoscopic surgery. HerResolve has the potential to reduce this diagnostic delay from years to months, improving patient and healthcare outcomes. The goal of HerResolve is to significantly shorten this timeline, enhancing patient care and results.

In April 2023, CCRM Fertility, a network of fertility clinics based in the US, acquired the New Hope Center for Reproductive Medicine for an undisclosed amount. This acquisition allows CCRM to expand its fertility services on the East Coast, providing greater access to high-quality fertility care, advanced testing, state-of-the-art laboratories, and in-house genetics and research, all contributing to leading success rates. The New Hope Center for Reproductive Medicine, also based in the US, is a fertility clinic offering a variety of services, including in vitro fertilization (IVF) to address female infertility.

Major players in the female infertility market are Pfizer Inc., Roche Holding AG, Merck And Co. Inc, Bayer AG, Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Commonwealth Serum Laboratories Ltd, Organon Theramex, Juniper Reproductive Health Ltd., Sumitomo Pharma, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Co., Mankind Pharma, Kissei Pharmaceutical Co Ltd, ASKA Pharmaceutical Co. Ltd., Fuji Pharma Co. Ltd., ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Hernova Lifesciences Holdings Ltd.

Europe was the largest region in the female infertility market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in female infertility report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the female infertility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Female infertility is defined as the inability of a woman to conceive after 12 months of regular, unprotected sexual intercourse (or 6 months for women aged 35 or older) or the inability to sustain a pregnancy. It is a multifactorial condition that results from various factors affecting the reproductive system.

The main treatments for female infertility include clomiphene citrate, gonadotropins, metformin, letrozole, and bromocriptine. Clomiphene citrate is commonly prescribed to stimulate ovulation in women with infertility. It can be administered in various forms, such as oral, parenteral, and others, and is available through hospital pharmacies, retail pharmacies, and online pharmacies.

The female infertility market research report is one of a series of new reports that provides female infertility market statistics, including female infertility industry global market size, regional shares, competitors with a female infertility market share, detailed female infertility market segments, market trends and opportunities, and any further data you may need to thrive in the female infertility industry. This female infertility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The female infertility market consists of revenues earned by entities by providing services such as hormonal therapy and treatment, genetic testing and counseling, ovulation induction, egg and sperm donation and intrauterine insemination. The market value includes the value of related goods sold by the service provider or included within the service offering. The female infertility market also includes sales of fertility drugs, ovulation test kits, fertility supplements, insemination devices and ultrasound machines for fertility monitoring. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.